What is Processa Pharmaceuticals 6-1 Month Momentum %?
6-1 Month Momentum % is the total return of the stock from 6-month ago to 1-month ago. As of today (2025-03-23), Processa Pharmaceuticals's 6-1 Month Momentum % is -61.03%.
The industry rank for Processa Pharmaceuticals's 6-1 Month Momentum % or its related term are showing as below:
PCSA's 6-1 Month Momentum % is ranked worse than 91.15% of 1480
companies
in the Biotechnology industry
Industry Median: -9.63
vs PCSA: -61.03
Competitive Comparison of Processa Pharmaceuticals's 6-1 Month Momentum %
For the Biotechnology subindustry, Processa Pharmaceuticals's 6-1 Month Momentum %, along with its competitors' market caps and 6-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Processa Pharmaceuticals's 6-1 Month Momentum % Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Processa Pharmaceuticals's 6-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where Processa Pharmaceuticals's 6-1 Month Momentum % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 6-1 Month Momentum % measures the total return to a stock over the past six months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
Processa Pharmaceuticals 6-1 Month Momentum % Related Terms
Thank you for viewing the detailed overview of Processa Pharmaceuticals's 6-1 Month Momentum % provided by GuruFocus.com. Please click on the following links to see related term pages.
Processa Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on utilizing its "regulatory science" approach in the development of Next Generation Chemotherapy ("NGC") oncology drug products. The company's strategic prioritization is to advance its pipeline of NGC proprietary small molecule oncology drugs. The NGC products are new chemical entities, but the company work by changing the metabolism, distribution, and/or elimination of already FDA-approved cancer drugs or their active metabolites while maintaining the mechanism of how the drug kills cancer cells. The three NGC treatments in its pipeline are - NGC-Capecitabine (also referred to as NGC-Cap), PCS3117, also referred to as NGC-Gemcitabine (NGC-Gem), PCS11T, also referred to as NGC-Irinotecan (NGC-Iri).
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
PCSA has been successfully added to your